PharmaRare & Genetic DiseasesUnited States Mirum Wins FDA Nod for FOP Pill, Challenging Regeneron The FDA has approved zilurgisertib (Atebrioz) for fibrodysplasia ossificans progressiva in patients aged 12 and older, making it the third approved FOP therapy and the second in five weeks. By Fernando PafumiSep 28, 20267 Comments
IHME: Global Health Funding Falls Another 5% in 2026 After Hitting Lowest Level Since 2012 Nov 16, 2026
You must be logged in to post a comment.